Related Experiment Videos
Immune responses to human papillomavirus.
1University of Cambridge, Department of Pathology, Tennis Court Road, Cambridge CB2 1QP, UK. mas@mole.bio.cam.ac.uk
Vaccine
|October 13, 2005
Summary
Human papillomavirus (HPV) evades immune detection through various mechanisms. However, new L1 virus-like protein vaccines show promise in preventing HPV infections.
Area of Science:
- Immunology
- Virology
- Vaccinology
Background:
- The immune system, comprising innate and adaptive immunity, combats foreign agents.
- Human papillomavirus (HPV) employs immune evasion strategies, hindering effective immune responses.
- HPV infects keratinocytes, residing in immune-privileged sites and having a short lifespan, which aids viral persistence.
Purpose of the Study:
- To investigate HPV's immune evasion mechanisms.
- To evaluate the efficacy and safety of novel prophylactic L1 virus-like protein vaccines against HPV.
Main Methods:
- Analysis of HPV's interaction with keratinocytes and immune signaling pathways.
- Review of clinical trial data for HPV L1 virus-like protein vaccines (HPV 16/18 and HPV 6/11/16/18).
Main Results:
- HPV downregulates interferon gene expression and utilizes keratinocyte biology to evade immune detection.
- Despite immune evasion, the immune system mounts localized cell-mediated responses against most HPV infections.
- Phase 3 trial data indicate HPV L1 vaccines are safe, elicit high antibody levels, and are effective in preventing HPV infection.
Conclusions:
- HPV possesses sophisticated mechanisms to evade the host immune system.
- Prophylactic L1 virus-like protein vaccines represent a safe and effective strategy for preventing HPV infections and hold significant public health potential.